GeNeuro Announces Approval of all Resolutions Proposed at Extraordinary General Meeting
69.1% of the Company’s share capital was represented at the EGM and resolutions were all unanimously approved Geneva, Switzerland, June 30, 2025 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that its shareholders have approved all resolutions proposed at its Extraordinary […]